title: Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
abstract: Traditional medicines have become the most productive source of leads for drugs development, particularly as anti-cancer agents. Various screening approaches are being applied. Sorafenib, a multikinase inhibitor, is used to treat primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer. A small library of compounds analogous to sorafenib were designed and screened for the treatment of liver cancer. Multiple members of the family in an assay panel of tyrosine kinase family and serine/threonine-protein kinase family, including VEGFR, Abl, Aurora A, p 38, Lck, Src, PDGFR, Flt3, c-RAF, c-KIT, MEK(MAPKK) were selected to test these compounds. Analysis of the selectivity patterns for these compounds shows specificity for many kinase families. IC₅₀ were measured for the selected compounds. Multiple compounds have very similar kinase inhibition profiles of VEGFR, Flt3, FGFR to that of sorafenib. The IC₅₀ of c-RAF of BB1 is lower than sorafenib. The IC₅₀ of c-RAF of BB3-12 is higher than that of sorafenib. For Flt3, IC₅₀ of BB1-4 is less than sorafenib. The IC₅₀ value of KDR of BB1-10 is less than sorafenib. especially against c-RAF, PDGFR, c-KIT, KDR compared to sorafenib. These compounds are potent Raf1 and Flt4 kinase inhibitors.
authors: State Key Laboratory for Diagnosis and Treatment of Infectious Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China.
authors: Yun-Qing
authors: YQ
authors: Qiu
authors: Jue
authors: J
authors: Zhou
authors: Xin-Shan
authors: XS
authors: Kang
authors: Jian-Zhong
authors: JZ
authors: Shen-Tu
authors: Lie-Ming
authors: LM
authors: Ding
authors: Fen-Lai
authors: FL
authors: Tan
authors: Jing
authors: J
authors: Guo
authors: Lan-Juan
authors: LJ
authors: Li
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001688:Biological Products / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D008519:Medicine, Traditional; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases
keywords: Clinical hepatotoxicity; Serine/threonine-protein kinase inhibitors; Sorafenib; Tyrosine kinase inhibitors
references: Anal Biochem. 1999 Mar 15;268(2):318-29
references: 10075822
references: Nat Rev Drug Discov. 2005 Jan;4(1):13-4
references: 15690599
references: Nat Rev Drug Discov. 2002 Jul;1(7):493-502
references: 12120256
references: J Biol Chem. 2011 Jun 24;286(25):22101-12
references: 21543337
references: Hepatology. 2002 Sep;36(3):525-31
references: 12198643
references: J Natl Cancer Inst. 2011 Jun 8;103(11):893-905
references: 21487100
references: Br J Clin Pharmacol. 2011 Jun;71(6):917-20
references: 21235620
references: Toxicol Sci. 2009 Apr;108(2):492-500
references: 19223659
references: Drugs. 2011 Mar 5;71(4):443-54
references: 21395357
references: Oncogene. 2000 Nov 20;19(49):5548-57
references: 11114734
references: J Biol Chem. 2002 Aug 30;277(35):31808-17
references: 12082106